# Domenica Lorusso

Source: https://onco.cc/people/domenica-lorusso/  
OnCo record `domenica-lorusso` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led KEYNOTE-A18, which showed adding pembrolizumab to chemoradiotherapy improves survival in locally advanced cervical cancer.

## Summary

Domenica Lorusso was principal investigator of KEYNOTE-A18, the ENGOT trial showing pembrolizumab with chemoradiotherapy improves progression-free and overall survival in high-risk locally advanced cervical cancer, the first systemic addition to chemoradiation to do so in two decades. She has led the MITO group's ovarian and endometrial trials and co-led studies of trastuzumab deruxtecan in gynaecological cancers.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: cervical; immunotherapy; italy
- Role: Director of Gynaecological Oncology, Humanitas San Pio X and Humanitas University, Milan
- Specialisms: Cervical cancer; Endometrial cancer; Ovarian cancer; Immunotherapy

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Lorusso%20D%5BAuthor%5D%20cervical%20pembrolizumab

## Connected records

- cancers: [Cervical cancer](https://onco.cc/cancers/cervical/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Trastuzumab deruxtecan](https://onco.cc/drugs/trastuzumab-deruxtecan/)
- institutions: [IRCCS Humanitas Research Hospital](https://onco.cc/institutions/humanitas/)
- trials: [KEYNOTE-A18 / ENGOT-cx11 / GOG-3047](https://onco.cc/trials/keynote-a18/)
- key papers: [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (overall survival)](https://onco.cc/key-papers/paper-keynote-a18-os-lancet-2024/), [KEYNOTE-A18: pembrolizumab with chemoradiotherapy for locally advanced cervical cancer (progression-free survival)](https://onco.cc/key-papers/paper-keynote-a18-pfs-lancet-2024/)

---
JSON: https://onco.cc/api/v1/entities/domenica-lorusso.json